Genetic Alteration Profiling in North Macedonian Lung Cancer Patients
Genes · 2025
DOI: 10.3390/genes16101177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Aleksandar Eftimov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer—BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA.
Methods
Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations.
Results
Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected.
Conclusions
Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.
- University Clinic of Radiotherapy and Oncology, Medical Faculty, 1000 Skopje, North Macedonia.
ORCID-Profile: Slavica Kostadinova Kunovska, Magdalena Bogdanovska Todorovska, Simonida Crvenkova, Gordana Petrushevska
Zitieren
APA
Eftimov, A., Jovanovic, R., Kostadinova Kunovska, S., Bogdanovska Todorovska, M., Ilievski, B., Zdravkovski, P., Komina, S., Krstevska, B., Crvenkova, S., Simonovska, M., & Petrushevska, G. (2025). Genetic Alteration Profiling in North Macedonian Lung Cancer Patients. Genes. https://doi.org/10.3390/genes16101177
Vancouver
Eftimov A, Jovanovic R, Kostadinova Kunovska S, Bogdanovska Todorovska M, Ilievski B, Zdravkovski P, et al. Genetic Alteration Profiling in North Macedonian Lung Cancer Patients. Genes. 2025. doi:10.3390/genes16101177
BibTeX
@article{Eftimov2025,
author = {Eftimov, Aleksandar and Jovanovic, Rubens and Kostadinova Kunovska, Slavica and Bogdanovska Todorovska, Magdalena and Ilievski, Boro and Zdravkovski, Panche and Komina, Selim and Krstevska, Blagica and Crvenkova, Simonida and Simonovska, Marija and Petrushevska, Gordana},
title = {Genetic Alteration Profiling in North Macedonian Lung Cancer Patients},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16101177}
}
EUVIMED